Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Northwest Biotherapeutics, Inc.
- Market Cap
- Unavailable
- Price
- $0.1696
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.97%
- Volume
- 3.2M
About
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Quick stats
Shares outstanding—
Computed float1.6B
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001072379
Websitehttps://www.nwbio.com
AI Summary
AI-generated1/10
minorbullishpartnership
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
Northwest Biotherapeutics signed a non-binding Memorandum of Understanding with SPIMACO, a leading Saudi pharma company, to commercialize DCVax-L for glioblastoma in Saudi Arabia and potentially the MENA region.
Under the revenue-sharing framework, SPIMACO will handle regulatory interactions with the SFDA and manage marketing and sales, while Northwest Biotherapeutics retains all IP and supplies the product.
The MOU also includes provisions for future technology transfer to enable localized manufacturing in Saudi Arabia, aligning with the country's Vision 2030 initiative.
Red flags
- Agreement is a non-binding MOU subject to definitive agreements
- No upfront payments or specific financial milestones disclosed